By Fineline Cube 
US biotechnology company Amgen (NASDAQ: AMGN) has announced positive outcomes from the double-blind, dose-ranging Phase II study of MariTide (maridebart cafraglutide), formerly known as AMG 133, at 52 weeks. This investigational antibody peptide conjugate, administered subcutaneously on a monthly or less frequent basis, has demonstrated significant potential in obesity treatment.
MariTide’s Impact on Weight Loss and Diabetes
In individuals with obesity or overweight without Type 2 diabetes, MariTide showed an average weight loss of up to 20% at week 52, with no indication of a weight loss plateau, suggesting the possibility of continued weight reduction beyond the study period. For those with obesity or overweight and Type 2 diabetes, who typically experience less weight loss with GLP-1 therapies, MariTide achieved an average weight loss of up to 17% and significantly lowered average hemoglobin A1C (HbA1c) levels by up to 2.2 percentage points at week 52.
Unique Mechanism of Action
MariTide’s mechanism of action involves activating the glucagon-like peptide-1 receptor (GLP-1R) and inhibiting the glucose-dependent insulinotropic polypeptide receptor (GIPR). This unique approach differentiates MariTide from other GIPR/GLP-1R dual agonists. By targeting multiple signaling pathways associated with obesity and metabolic disorders, MariTide is expected to effectively manage weight and improve metabolic health.-Fineline Info & Tech